MYOCD, myocardin, 93649

N. diseases: 79; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007193
Disease: Cardiomyopathy, Dilated
Cardiomyopathy, Dilated 		0.210 Biomarker group MGD
CUI: C0013274
Disease: Patent ductus arteriosus
Patent ductus arteriosus 		0.200 Biomarker disease MGD
CUI: C0036572
Disease: Seizures
Seizures 		0.100 GeneticVariation phenotype CLINVAR
CUI: C1843367
Disease: Poor school performance
Poor school performance 		0.100 GeneticVariation phenotype CLINVAR
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.020 Biomarker disease BEFREE <b>Conclusions:</b> These data indicate that TCF21 antagonizes the MYOCD-SRF pathway through multiple mechanisms, further establishing a role for this CAD associated gene in fundamental SMC processes and indicating the importance of smooth muscle response to vascular stress and phenotypic modulation of this cell type in CAD risk. 31815603 2020
CUI: C0346957
Disease: Disseminated Malignant Neoplasm
Disseminated Malignant Neoplasm 		0.010 AlteredExpression phenotype BEFREE Disseminated cancer cells employ L1CAM (cell adhesion molecule L1) to spread on capillaries and activate the mechanotransduction effectors YAP (Yes-associated protein) and MRTF (myocardin-related transcription factor). 30038252 2018
CUI: C0007193
Disease: Cardiomyopathy, Dilated
Cardiomyopathy, Dilated 		0.210 AlteredExpression group BEFREE Myocardin and HOP mRNA levels were estimated by both northern blot hybridization and semiquantitative RT-PCR in human ventricular preparations in end-stage failure due to dilated cardiomyopathy (DCM), as well as in nonfailing donor hearts. 12920479 2003
CUI: C1449563
Disease: Cardiomyopathy, Familial Idiopathic
Cardiomyopathy, Familial Idiopathic 		0.020 AlteredExpression disease BEFREE Myocardin and HOP mRNA levels were estimated by both northern blot hybridization and semiquantitative RT-PCR in human ventricular preparations in end-stage failure due to dilated cardiomyopathy (DCM), as well as in nonfailing donor hearts. 12920479 2003
CUI: C3665464
Disease: Dementia due to Alzheimer's disease (disorder)
Dementia due to Alzheimer's disease (disorder) 		0.010 Biomarker disease BEFREE MYOCD in vivo gene transfer to mouse pial arteries increased contractile protein content and diminished CBF responses produced by brain activation in wild-type mice and in two AD models, the Dutch/Iowa/Swedish triple mutant human amyloid beta-peptide (Abeta)-precursor protein (APP)- expressing mice and APPsw(+/-) mice.Silencing Srf had the opposite effect. 17215356 2007
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.050 AlteredExpression group BEFREE Myocardin expression is reduced in multiple types of human tumors. 17292825 2007
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.020 AlteredExpression phenotype BEFREE Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. 19198601 2009
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.020 Biomarker phenotype BEFREE Myocardin had the opposite effects of miR‑135b, which suppressed proliferation, migration and invasion in MG63 cells. 25190111 2014
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.040 AlteredExpression disease BEFREE Myocardin levels are reduced during atherosclerosis, in association with phenotypic switching of smooth muscle cells. 25614278 2015
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.040 AlteredExpression disease BEFREE Myocardin levels are reduced during atherosclerosis, in association with phenotypic switching of smooth muscle cells. 25614278 2015
CUI: C1851710
Disease: LATERAL MENINGOCELE SYNDROME
LATERAL MENINGOCELE SYNDROME 		0.030 Biomarker disease BEFREE MYOCD, a key gene associated with smooth muscle differentiation, is amplified in a subset of both retroperitoneal and extremity LMS. 26541895 2016
CUI: C1863753
Disease: LIMB-MAMMARY SYNDROME
LIMB-MAMMARY SYNDROME 		0.030 Biomarker disease BEFREE MYOCD, a key gene associated with smooth muscle differentiation, is amplified in a subset of both retroperitoneal and extremity LMS. 26541895 2016
CUI: C1608408
Disease: Malignant transformation
Malignant transformation 		0.020 Biomarker phenotype BEFREE Myocardin is frequently repressed during human malignant transformation, and restoration of myocardin expression in sarcoma cells contributes to the inhibition of malignant growth. 27156566 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.030 AlteredExpression group BEFREE Myocardin is frequently repressed during human malignant transformation, and restoration of myocardin expression in sarcoma cells contributes to the inhibition of malignant growth. 27156566 2016
CUI: C3888088
Disease: SMITH-MCCORT DYSPLASIA 1
SMITH-MCCORT DYSPLASIA 1 		0.020 AlteredExpression disease BEFREE Myocardin expression represents a contractile and differentiated SMC phenotype. 28012646 2017
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.010 Biomarker disease BEFREE Myocardin expression is upregulated upon H<sub>2</sub>O<sub>2</sub> and ischemia/reperfusion, and knockdown of myocardin inhibits autophagy and attenuates myocardial infarction. p53 regulates cardiomyocytes autophagy and myocardial ischemia/reperfusion injury by regulating myocardin expression. 29295976 2018
CUI: C0018801
Disease: Heart failure
Heart failure 		0.010 AlteredExpression disease BEFREE A possible dual consequence of increased myocardin and decreased HOP expression levels on serum response factor-dependent cardiac-specific expression in the normal heart and at heart failure is discussed. 12920479 2003
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure 		0.010 AlteredExpression disease BEFREE A possible dual consequence of increased myocardin and decreased HOP expression levels on serum response factor-dependent cardiac-specific expression in the normal heart and at heart failure is discussed. 12920479 2003
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.050 Biomarker group BEFREE At stage I, among the tumors reclassified as molecular leiomyosarcomas (ie, genomic index ≥10), the poor prognostic markers were: 5p gain (overall survival P=0.0008), genomic index at cut-off=35 (overall survival P=0.0193), 13p loss including RB1 (overall survival P=0.0096) and 17p gain including MYOCD gain (overall survival P=0.0425). 29327710 2018
CUI: C0023269
Disease: leiomyosarcoma
leiomyosarcoma 		0.030 Biomarker disease BEFREE At stage I, among the tumors reclassified as molecular leiomyosarcomas (ie, genomic index ≥10), the poor prognostic markers were: 5p gain (overall survival P=0.0008), genomic index at cut-off=35 (overall survival P=0.0193), 13p loss including RB1 (overall survival P=0.0096) and 17p gain including MYOCD gain (overall survival P=0.0425). 29327710 2018
CUI: C0004238
Disease: Atrial Fibrillation
Atrial Fibrillation 		0.400 GeneticVariation disease GWASCAT Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. 30061737 2018